MedPath

F. Hoffmann-La Roche AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

280

Active:162
Completed:10

Trial Phases

5 Phases

Phase 1:199
Phase 2:13
Phase 3:30
+2 more phases

Drug Approvals

4

PHILIPPINES:4

Drug Approvals

Recormon

Approval Date
Jul 14, 2025
PHILIPPINES

Tecentriq

Approval Date
Jul 14, 2025
PHILIPPINES

Kadcyla

Approval Date
Jul 14, 2025
PHILIPPINES

Kadcyla

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (251 trials with phase data)• Click on a phase to view related trials

Phase 1
199 (79.3%)
Phase 3
30 (12.0%)
Phase 2
13 (5.2%)
phase_1_2
6 (2.4%)
1 (0.4%)
Not Applicable
1 (0.4%)
Phase 4
1 (0.4%)
No trials found

News

Lyme Disease Pipeline Shows Promise with 7+ Therapies in Development as Valneva-Pfizer Vaccine Advances

DelveInsight's 2025 pipeline report identifies 7+ companies developing novel Lyme disease therapies, with emerging treatments including BLB 400, FP-100, CT38, TP-05, and VLA15 expected to significantly impact the market.

Delhi High Court Rules Against Roche in Pertuzumab Patent Disclosure Case, Clarifies Section 104A Requirements for Biologics

The Delhi High Court denied F. Hoffmann-La Roche's request to access Zydus Lifesciences' manufacturing process for their Pertuzumab biosimilar, ruling that Roche failed to meet mandatory requirements under Section 104A of the Patents Act.

Delhi High Court Halts Natco Pharma's Generic Risdiplam Launch in Roche Patent Dispute

The Delhi High Court has ordered Natco Pharma to maintain status quo on launching its generic version of Risdiplam, a treatment for spinal muscular atrophy, until April 2 amid Roche's patent infringement appeal.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.